CHEK2 and breast carcinoma: Although these early studies found that the frequency of c.1100delC mutations was enriched among breast cancer patients with early and/or double primary tumors and in multiple cancer families, an incomplete penetrance of c.1100delC in cancer families and a high prevalence of the variant in controls substantially distorted CHEK2′s credit as a clinically considerable predisposing gene.